Characterization of anti-IL-1α autoantibodies in the sera from healthy humans

doi:10.1016/0162-3109(94)90045-0

Immunopharmacology

Volume 27, Issue 2, March–April 1994, Pages 107-118

Immunopharmacology

https://doi.org/10.1016/0162-3109(94)90045-0 Get rights and content

Abstract

Previously, we reported that pooled normal human serum contained anti-IL-1α autoantibodies. Further characterization studies have been undertaken with sera from individual healthy humans. Molecular exclusion chromatography demonstrated that 9 of 38 test sera contained anti-IL-1α autoantibodies that specifically bound ¹²⁵I-IL-1α. The autoantibodies formed immune complexes composed of either one IgG or two IgG molecules bound to one ¹²⁵I-IL-1α molecule. The data suggest that the autoantibodies recognize at least two separate antigenic sites on IL-1α. The autoantibodies neutralized IL-1α induced IL-2 secretion by mouse thymocytes (EL-4 NOB-1). Further, in an in vitro competitive receptor binding assay, the autoantibodies completely blocked ¹²⁵I-IL-1α binding to recombinant human IL-1 receptor expressed on CHO cells. Our previous studies have established a correlation between inhibition of ¹²⁵I-IL-1α binding to receptor bearing cells and neutralization of IL-1 bioactivity in vitro and in vivo. These data suggest that development of anti-IL-1α autoantibodies may play a significant role in modulating the effects of high local or systemic concentrations of IL-1α.

References (27)

K. Bendtzen et al.
Autoantibodies to Cytokines-Friends or Foes?
Immunol. Today
(1990)
W. Borth et al.
Binding of recombinant interleukin-1β to the third complement component and α₂-macroglobulin after activation of serum by immune complexes
Blood
(1990)
W. Borth et al.
Identification of α₂-macroglobulin as a cytokine binding plasma protein
J. Biol. Chem.
(1989)
J.G. Giri et al.
Identification of soluble interleukin
J. Biol. Chem.
(1990)
M. Svenson et al.
Effects of human anti-IL-1α autoantibodies on receptor binding and biological activies of IL-1
Cytokine
(1992)
K.L. Bost et al.
Individuals infected with HIV possess antibodies against IL-2
Immunology
(1988)
D.B. Carter et al.
Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein
Nature
(1990)
R.T. Chizzonite et al.
Two high-affinity interleukin receptors represent separate gene products
J.-M. Dayer et al.
Natural inhibitors and antagonists of interleukin-1
S.K. Dower et al.
The cell surface receptors for interleukin-1α and interleukin-1β are identical
Nature
(1986)

S.P. Eisenberg et al.

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

Nature

(1990)

A. Formsgaard et al.

Autoantibodies to tumor necrosis factor α in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections

Scand. J. Immunol.

(1989)

F.S.D. Giovine et al.

Interleukin 1: the first interleukin

Immunol. Today

(1990)

Cited by (10)

Biologic basis for interleukin-1 in disease
1996, Blood
To understand the role of the proinflammatory cytokine interleukin-1 (IL-1) in disease, investigators have studied how production of the different members of the IL-1 family is controlled, the various biologic activities of IL-1, the distinct and various functions of the IL-1 receptor (IL-1R) family, and the complexity of intracellular signaling. Mice deficient in IL-1β, IL-1β converting enzyme, and IL-1R type I have also been studied. Humans have been injected with IL-1 (either IL-1α or IL-1β) for enhancing bone marrow recovery and for cancer treatment. The IL-1–specific receptor antagonist (IL-1Rα) has also been tested in clinical trials. The topics discussed in this review include production and activities of IL-1 and IL-1Rα molecules, the effects of IL-1 on gene expression, functions of cell-bound and soluble IL-1 receptors, the importance of the IL-1R accessory protein, newly discovered signal transduction pathways, naturally occurring cytokines limiting IL-1 production or activity, the effects of blocking cyclooxygenase and nitric oxide, and the outcomes of IL-1 and IL-1Rα in human trials. Special attention is paid to IL-1β converting enzyme and programmed cell death. The roles of IL-1 in hematopoiesis, leukemia, atherosclerosis, and growth of solid tumors are also discussed. This is a lengthy review, with 586 citations chosen to illustrate specific areas of interest rather than a compendium of references. At the end of each section, a short commentary summarizes what the author considers established or controversial topics linking the biology of IL-1 to mechanisms of disease.
Beware of antibodies to dietary proteins in "antigen-specific" immunoassays! falsely positive anticytokine antibody tests due to reactivity with bovine serum albumin in rheumatoid arthritis (The Swedish TIRA Project)
2011, Journal of Rheumatology
Cytokine/antibody complexes: An emerging class of immunostimulants
2009, Current Pharmaceutical Design
Recurrent staphylococcal cellulitis and subcutaneous abscesses in a child with autoantibodies against IL-61
2008, Journal of Immunology
Anti-interleukin 1α autoantibodies
2002, Annals of the Rheumatic Diseases
Increased incidence of autoantibodies to interleukin-1α in rheumatoid arthritis with interstitial lung disease
2000, Respirology

View all citing articles on Scopus

View full text

Characterization of anti-IL-1α autoantibodies in the sera from healthy humans

Abstract

Immunol. Today

Blood

J. Biol. Chem.

J. Biol. Chem.

Cytokine

Individuals infected with HIV possess antibodies against IL-2

Immunology

Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein

Nature

Two high-affinity interleukin receptors represent separate gene products

Natural inhibitors and antagonists of interleukin-1

The cell surface receptors for interleukin-1α and interleukin-1β are identical

Nature

Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist

Nature

Autoantibodies to tumor necrosis factor α in healthy humans and patients with inflammatory diseases and gram-negative bacterial infections

Scand. J. Immunol.

Interleukin 1: the first interleukin

Immunol. Today